business
Hosted by Kison Patel · business · EN · 437 episodes
M&A Science, hosted by Kison Patel (Founder & CEO of DealRoom), is your go-to podcast for mastering the art of mergers and acquisitions. Each week, Kison and his expert guests from leading brands like Xerox, FastLap, and Cisco dig deep into real-world M&A strategies, offering actionable insights to optimize your M&A practice.Whether you're an experienced practitioner or new to the field, M&A Science provides practical advice on key topics like sourcing, due diligence, integration, divestitures, and more. With over 300 episodes, this podcast is the premier thought leadership resource designed to streamline your deal-making process.Start listening today and visit mascience.com/podcast to access over 300 episodes. Brought to you by DealRoom, the leading M&A optimization platform used by the best M&A teams around the world
Required Pod Score for this show. PitchCentric checks your profile against host openness, topical fit, and audience signals before you generate a pitch.
Contact path
Verified email
Booking probability
38%
Guest openness
Selective
Sign up to generate a grounded pitch for M&A Science.
Signup to Generate a PitchM&A Science, hosted by Kison Patel (Founder & CEO of DealRoom), is your go-to podcast for mastering the art of mergers and acquisitions. Each week, Kison and his expert guests from leading brands like Xerox, FastLap, and Cisco dig deep into real-world M&A strategies, offering actionable insights to optimize your M&A practice.
M&A Science is hosted by Kison Patel. The show has published 437 episodes to date.
Recent episodes include "How to Get to Yes" (22 October 2026, 55 minutes), "M&A Horror Stories" (15 October 2026, 26 minutes), and "The Vendor Trap That Derails Carve-Outs" (8 October 2026, 54 minutes).
M&A Science publishes roughly weekly, with episodes averaging 52 minutes across 437 episodes.
Booking probability for M&A Science is 38%, and the host is rated Selective on guests. M&A Science requires a Pod Score of 80 or higher. M&A Science's contact route on record: verified email.
The strongest fits for M&A Science are Business & Management Consulting. M&A Science has a business audience.
Kison Patel hosts M&A Science, a business show with 437 episodes published.
Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.
Episode #438
Most people assume the hard part of an M&A deal is getting the contract signed. However, Meg Cavanaugh, SVP of Legal at Commvault (NASDAQ: CVLT), has spent her career proving otherwise. Meg worked in-house at three...
Episode #437
Every M&A practitioner has a deal that still makes them wince. This episode collects the ones that never make it into a case study. Kison pulled real stories from corporate development leaders, bankers, attorneys, and...
Episode #436
Days before closing a carve-out, Danielle Fortier's team found the seller's vendor list was off by dozens of vendors. Danielle, a partner at Cooley with four corporate carve-outs closed this year, explains why...
Episode #435
Jerry Cedicci never says, "trust me." He builds trust, then lets the deal speak for itself. This is Part 2 of Kison's conversation with Jerry, The mentor who started with a French bakery and went on to build hundreds of...
Episode #434
Twenty years before M&A Science existed, Kison Patel learned how to spot a deal from a real estate developer named Jerry Cedicci. This episode tells Jerry's story: orphaned in France at age 7, he arrived in Chicago in...
Episode #433
A rollup can look attractive at signing: cash today, equity in a larger platform, and the promise of participating in what gets built next. But sellers rarely spend as much time understanding what sits above that...
Episode #432
Integration problems often get blamed on culture after close. The real issue may have started earlier, when leaders were never given enough clarity on how to operate inside the new company. Kim Jones is an HR Director...
Episode #431
Praveen Ghanta , Founder and CEO of DevHawk Signing the LOI can feel like you've won. For the seller, it may actually be the moment when the balance of power starts moving the other way. Praveen Ghanta learned that...
Episode #430
Richard Chow, Partner at PJT Partners (NYSE: PJT) Secondary deals are often judged by a single metric: the discount. Richard Chow thinks that's the wrong place to start. After spending most of his career investing in...
Episode #429
Bill Stone, Founder and CEO of SS&C How do you keep buying companies without eventually losing control of the company you built? SS&C Technologies founder and CEO Bill Stone has spent four decades avoiding exactly that...
Episode #428
Aaron Binstock , Partner, Co-Head of Private Equity Practice at Cooley LLP AI can now draft, review, and benchmark deal documents in a fraction of the time it used to take, but knowing when to trust the output is a...
Episode #427
Jennifer Lipschultz , Sr. Director Merger & Acquisition Integration and Corporate Project Management Due diligence covers deal terms, but it doesn't cover what happens once you're running payroll, benefits, and banking...
Episode #426
Derek Liu, M&A Partner at Baker McKenzie AI talent deals are no longer small acquihires built around a simple price per engineer. Some now carry billion-dollar price tags, forcing buyers to rethink deal structure...
Episode #425
Andrew Morbitzer, VP of Corporate Development, Life360 (ASX: 360) Your standard teaser tells a buyer everything about your company and nothing about why you fit their strategy right now. When sellers expect the buyer to...
Episode #424
Shawn Rodricks, Head of M&A - Independent Consultant If you scale the deal flow without the operating infrastructure to match it, things break fast. The playbook is a document nobody opens, closing weeks turn into fire...
Episode #423
Jeremy Segal, Executive Vice President of Corporate Development, Progress (NASDAQ: PRGS) Buyers who mistake a high LOI bid for a winning strategy are easy prey for sellers who know the growth equity playbook. Jeremy...
Episode #422
Haseeb Jawad, VP and Head of Corporate Development, Commvault (NASDAQ: CVLT) The people who leave post-close are usually the ones the deal depended on. Which means the problem starts with how you read culture before LOI...
Episode #421
Matt Arsenault, VP of Corporate Development & Strategic Alliances at Jamf Venture-backed companies are priced at their future state, not their current revenue. When growth stalls and another fundraising round stops...
Episode #420
Nathan Rust , Lutz Lehmann , Troy Pospisil , Jeremy Segal , Patrick Mumman , Tej Brahmbhatt , George Helock , and Angie Astle Eight deal professionals share the M&A moments that never make the CIM. A birthday cake in a...
Episode #419
Brent Baxter , Sam Delestienne , Steve Hoffman , John Strenger , and Matt Melsen Winning a banker-run auction at 5% under the highest bid. Closing a deal when co-sellers have not spoken in months. Getting through 22...
Recent guests on M&A Science. Study who booked and why before you pitch.
board-certified dentist and sleep medicine specialist, Moosylvania
Corporate Product Manager in the Architecture Department, Management & Organizations
Founder of Bioethics International and Creator of Good Pharma Scorecard, Washington State University College of Pharmacy and Pharmaceutical Sciences
Constable, Internet Crimes Against Children (ICAC) unit, The Woodlands, Texas
PitchCentric classifies M&A Science under these industries. Guests from them are the closest fit, and each links to the best podcasts in that industry.
Is this podcast yours and you'd like to remove or correct details? Request removal or email privacy@pitchcentric.com.
Questions about the free trial? See the pricing FAQ